67308-25-2

Usage

Uses

Used in Pharmaceutical Research and Development:
(S)-N-Boc-6-fluorotryptophan is used as a key intermediate in the synthesis of pharmaceutical compounds for its ability to alter the properties of tryptophan, which can lead to the creation of new drugs with improved efficacy or selectivity.
Used in Biochemistry:
(S)-N-Boc-6-fluorotryptophan serves as a valuable research tool in biochemistry for studying protein-ligand interactions, given the modification of the tryptophan molecule that can affect binding affinities and specific interactions with biological targets.
Used in Materials Science:
In the field of materials science, (S)-N-Boc-6-fluorotryptophan is utilized for its potential to contribute to the development of novel materials with unique properties, stemming from the altered characteristics of the tryptophan molecule when the fluorine atom is introduced.
Each application underscores the compound's versatility and the importance of its structural modifications in advancing scientific understanding and technological innovation across different industries.

InChI:InChI=1/C16H19FN2O4/c1-16(2,3)23-15(22)19-13(14(20)21)6-9-8-18-12-7-10(17)4-5-11(9)12/h4-5,7-8,13,18H,6H2,1-3H3,(H,19,22)(H,20,21)/t13-/m0/s1

Upstream product

• 16626-02-1 5-fluoro-L-tryptophan 
• 114926-41-9 (S)-2-((tert-butoxycarbonyl)amino)-3-(5-fluoro-1H-indol-3-yl)propanoic acid 
• 19310-00-0 6-fluoro-L-tryptophan 
• 58632-95-4 2-(tert-Butoxycarbonyloxyimino)-2-phenylacetonitrile 
• 7730-20-3 DL-6-fluorotryptophan 
• 24424-99-5 di-tert-butyl dicarbonate 

Relevant academic research and scientific papers

A class of DL-tryptophan compounds, preparation method and applications thereof

The invention provides a DL-tryptophan compound represented by a general formula I or a pharmaceutically acceptable salt thereof, a preparation method and applications thereof, especially applicationsin preparation of RANKL inhibitors. According to the DL-tryptophan compound or the pharmaceutically acceptable salt thereof, an OPG-RANKL-RANK signal system can be intervened by inhibiting the interaction of RANKL-RANK, and the activity of RANKL in osteoclast precursor cells is regulated and controlled, so that formation of osteoclasts is inhibited, and bone resorption is reduced; and the DL-tryptophan compound or the pharmaceutically acceptable salt thereof is expected to play a role in preventing and treating bone metabolic diseases, and brings good news to bone metabolic disease patients.

Development of Small-Molecules Targeting Receptor Activator of Nuclear Factor-κB Ligand (RANKL) - Receptor Activator of Nuclear Factor-κB (RANK) Protein-Protein Interaction by Structure-Based Virtual Screening and Hit Optimization

Targeting RANKL/RANK offers the possibility of developing novel therapeutic approaches to treat bone metabolic diseases. Multiple efforts have been made to inhibit RANKL. For example, marketed monoclonal antibody drug Denosumab could inhibit the maturation of osteoclasts by binding to RANKL. This study is an original approach aimed at discovering small-molecule inhibitors impeding RANKL/RANK protein interaction. We identified compound 34 as a potent and selective RANKL/RANK inhibitor by performing structure-based virtual screening and hit optimization. Disruption of the RANKL/RANK interaction by 34 effectively inhibits RANKL-induced osteoclastogenesis and bone resorption. The expression of osteoclast marker genes was also suppressed by treatment of 34. Furthermore, 34 markedly blocked the NFATc1/c-fos pathway. Thus, our current work demonstrates that the chemical tractability of the difficult PPI (RANKL/RANK) target by a small-molecule compound 34 offers a potential lead compound to facilitate the development of new medications for bone-related diseases.

Somatostatin analogs having a substituted tryptophyl residue in position eight

Tetradecapeptides of the formula STR1 in which A represents L, D or DL 5- or 6- fluoro-, bromo-,chloro- or iodotryptophyl, or a therapeutically acceptable acid addition salt thereof, their preparation and intermediates for their preparation are disclosed. The tetradecapeptides are useful for inhibiting the release of growth hormone. Compositions and methods for their use also are disclosed.